AlphAIalphai — Financial news for AI agents
finanznachrichten.deSEP 42 min read$NVS

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

Original reporting
finanznachrichten.de
Published Sep 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$NVS
Bearish
medium confidence
Mentioned
$NVS
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$NVSBearishMed
01

Why it matters

The failure to reduce major adverse cardiovascular events may lead to a re‑evaluation of the drug's commercial potential and affect upcoming pipeline guidance.

02

Market read

Primary news for Novartis; potential short‑term stock downside and sector‑wide caution for Lp(a) therapeutics.

03

What to watch

The trial still demonstrated significant Lp(a) reduction, which could support future combination strategies or regulatory discussions.

Relevance 8/10Novelty 8/10Timing: Sept 4 2026 (today)

Background

Novartis disclosed the topline results of its Lp(a)HORIZON Phase III trial, a key study for the investigational antisense drug pelacarsen.

Company-level read

Ticker impact

$NVSBearishMedium confidence
Context

Novartis announced its Phase III pelacarsen trial failed to meet the primary cardiovascular endpoint.

Expected impact

downward pressure on NVS share price in the short term

Evidence & confidence

Phase III failure is material news for a large pharma; investors may reassess pipeline value and upcoming guidance.

Market effects

Sector

May dampen sentiment for Lp(a) targeting therapies and affect biotech peers developing similar antisense drugs.

Regional

European pharma stocks could see modest pullback as investors reassess cardiovascular pipeline risk.

Global

Limited to healthcare sector; broader market impact minimal.

Counterpoint

What could challenge this read

Some investors may view the Lp(a) lowering data as a long‑term asset, betting on future indications despite the missed endpoint.

Key entities

  • Company
    Novartis AG

    Swiss‑based pharmaceutical giant developing pelacarsen.

  • Drug
    Pelacarsen

    Investigational antisense oligonucleotide targeting lipoprotein(a).

Read at source← All news

Related articles

SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 4
$NVSMedAI 8/10

Novartis halts CAR T therapy trials after patient deaths

Novartis halted clinical trials for its CAR T therapy rapcabtagene autoleucel after three patient deaths due to severe immune reactions. Bristol Myers Squibb also paused trials for its competitor product zola-cel, citing reversible inflammatory events. Both therapies target CD19, a protein linked to immune responses, but can cause severe immune reactions. Neither company has identified a cause.

bioxconomy.com2 min
SEP 4
$NVSMedAI 8/10

Novartis commits $3.2B to subcutaneous delivery

Novartis has secured exclusive rights to develop and commercialize subcutaneous versions of several products using Alteogen’s ALT-B4 technology. The deal could be worth up to $3.223 billion plus royalties if all options and milestones are met. This technology could potentially be used across multiple products, helping Novartis prepare for patent losses on major medicines. Alteogen has also signed similar deals with Biogen and GSK’s Tesaro. Novartis is also investing in other delivery technologie

european-biotechnology.com2 min
SEP 4
$NVSMedAI 8/10

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions. The pause affects trials for autoimmune and neurological disorders. Novartis is reviewing the deaths and sharing information with health authorities. Bristol Myers also paused studies of its rival CAR T-cell treatment zola-cel. Novartis shares rose 4% on Tuesday.

2lt.com.au2 min
SEP 4
$NVSHighAI 9/10

Novartis Signs $3.22bn Alteogen SC Drug Delivery Deal

Novartis agreed to a $3.22bn deal with Alteogen for ALT-B4, a subcutaneous drug delivery technology. The agreement includes option fees, milestones, and royalties. Novartis gains global rights to develop subcutaneous versions of its biologic products, expanding its portfolio in a competitive market.

zenopa.com2 min